Ligand Pharmaceuticals (LGND) Stock Forecast, Price & News

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Ligand Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" LGND shares.
View LGND analyst ratings or view top-rated stocks.

4 analysts have issued 12-month price targets for Ligand Pharmaceuticals' shares. Their LGND share price forecasts range from $90.00 to $144.00. On average, they predict the company's share price to reach $109.75 in the next twelve months. This suggests a possible upside of 86.8% from the stock's current price.
View analysts price targets for LGND or view top-rated stocks among Wall Street analysts.

Ligand Pharmaceuticals' stock was trading at $66.80 at the beginning of the year. Since then, LGND stock has decreased by 12.1% and is now trading at $58.75.
View the best growth stocks for 2023 here.

Ligand Pharmaceuticals saw a decline in short interest during the month of September. As of September 15th, there was short interest totaling 825,000 shares, a decline of 6.2% from the August 31st total of 879,200 shares. Based on an average trading volume of 94,200 shares, the short-interest ratio is currently 8.8 days. Approximately 5.1% of the shares of the company are sold short.
View Ligand Pharmaceuticals' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Monday, November 6th 2023.
View our LGND earnings forecast.

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) posted its quarterly earnings results on Tuesday, August, 8th. The biotechnology company reported $1.42 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.76 by $0.66. The biotechnology company earned $26.37 million during the quarter, compared to analyst estimates of $24.74 million. Ligand Pharmaceuticals had a trailing twelve-month return on equity of 6.82% and a net margin of 14.54%. The company's revenue was down 47.4% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.14) earnings per share.

ETFs with the largest weight of Ligand Pharmaceuticals (NASDAQ:LGND) stock in their portfolio include Invesco Pharmaceuticals ETF (PJP), iShares Genomics Immunology and Healthcare ETF (IDNA), Virtus LifeSci Biotech Products ETF (BBP), Invesco S&P SmallCap Health Care ETF (PSCH), Franklin Genomic Advancements ETF (HELX), SPDR S&P Pharmaceuticals ETF (XPH) and Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL).iShares U.S. Pharmaceuticals ETF (IHE).

Ligand Pharmaceuticals updated its FY 2023 earnings guidance on Wednesday, September, 27th. The company provided earnings per share (EPS) guidance of $5.10-$5.25 for the period, compared to the consensus EPS estimate of $4.98. The company issued revenue guidance of $124.00 million-$126.00 million, compared to the consensus revenue estimate of $127.05 million.

1 employees have rated Ligand Pharmaceuticals Chief Executive Officer John L. Higgins on Glassdoor.com. John L. Higgins has an approval rating of 100% among the company's employees. This puts John L. Higgins in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Ligand Pharmaceuticals investors own include Jazz Pharmaceuticals (JAZZ), Micron Technology (MU), NVIDIA (NVDA), Alibaba Group (BABA), Intel (INTC), AbbVie (ABBV), Netflix (NFLX), Cisco Systems (CSCO), Illumina (ILMN) and Gilead Sciences (GILD).

Ligand Pharmaceuticals trades on the NASDAQ under the ticker symbol "LGND."

Shares of LGND stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of LGND stock can currently be purchased for approximately $58.75.

Ligand Pharmaceuticals (NASDAQ:LGND) has a market capitalization of $1.02 billion and generates $196.24 million in revenue each year. The biotechnology company earns $-33,360,000.00 in net income (profit) each year or $1.44 on an earnings per share basis.

Ligand Pharmaceuticals' mailing address is 3911 SORRENTO VALLEY BLVD SUITE 110, SAN DIEGO CA, 92121. The official website for the company is www.ligand.com. The biotechnology company can be reached via phone at (858) 550-7500, via email at investors@ligand.com, or via fax at 858-550-1826.